• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002437.SZ
Share

HARBIN GLORIA PHARMACEUTICALS Co., LTD Stocks

CN¥ 2.9Last Updated 03.07.2026

Issuer Rating

5/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 797.13M

CN¥ 2.9
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Harbin Gloria Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical enterprise primarily focused on the research, development, manufacturing, and commercialization of various medicinal products within the People's Republic of China. The company's comprehensive portfolio addresses a broad spectrum of therapeutic areas, including cardiac and cerebrovascular health, skeletal muscle system support, and urinary tract conditions. It also provides vitamins and minerals, as well as medications for oncology, endocrine disorders, anti-infective treatments, respiratory ailments, antihistamine purposes, and peptic concerns, among other pharmaceutical goods. Established in 2000, the firm's headquarters are located in Harbin, also situated in the People's Republic of China.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 002437.SZ is 3.2 and suggests 9.12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommend

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

06.07.2026 12:14

Goldman has lowered its forecast for the yen: the bank expects it to reach 165 per dollar and sees an opportunity in the carry trade

06.07.2026 10:41

Morning Highlights: Brent Prices Fall, easyJet Agrees to Takeover, and Nvidia Delay

06.07.2026 10:25

Fed and ECB Minutes, Pepsi and Delta Earnings: What Investors Need to Know This Week

05.07.2026 21:00

iHerb Is Set to Go Public, and Vimeo's Owner Is Making Its Debut: Key Facts About the IPOs by July 5

05.07.2026 18:01

Not everyone believes the dollar will strengthen in the future: what will determine its exchange rate

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026